scholarly journals Diffuse Melanosis and Ascites due to Metastatic Malignant Melanoma

2008 ◽  
Vol 8 ◽  
pp. 556-557 ◽  
Author(s):  
Elena Sendagorta ◽  
Angel Pizarro ◽  
Marta Feito ◽  
Matias Mayor ◽  
Paloma Ramírez ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Metastatic Melanoma ◽  
Female Patient ◽  
Metastatic Malignant Melanoma ◽  
Current Evidence ◽  
Rare Entity ◽  
Skin Hyperpigmentation

We present a female patient who developed mucosal and skin hyperpigmentation due to metastatic malignant melanoma. Diffuse cutaneus melanosis is a rare entity that complicates a small percentage of metastatic melanomas, confering a fatal prognosis. We discuss briefly the current evidence on pathogenesis of melanosis arising from metastatic melanoma.

scholarly journals Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma

2019 ◽  
Vol 12 (1) ◽  
pp. 29-32 ◽  
Author(s):  
Keren Rouvinov ◽  
Karen Nalbandyan ◽  
Victor Kozlov ◽  
Nir Peled ◽  
Alexander Yakobson
Keyword(s):  
Malignant Melanoma ◽  
Aplastic Anemia ◽  
Metastatic Melanoma ◽  
Active Treatment ◽  
Melanoma Patient ◽  
Case Reports ◽  
Metastatic Malignant Melanoma ◽  
Line Treatment ◽  
Metastatic Melanoma Patient ◽  
Advanced Line

Nivolumab is an active treatment in patients with metastatic melanoma. We report a case of a patient with metastatic malignant melanoma who was given nivolumab as an advanced-line treatment. She received nivolumab 3 mg/kg every 2 weeks for 4 cycles and developed aplastic anemia. To the best of our knowledge, there are only three published case reports that have shown aplastic anemia in patients who have been treated by immunotherapy. This is the first report of a lethal aplastic anemia during nivolumab monotherapy in a metastatic melanoma patient.

Metastatic malignant melanoma of the larynx

2001 ◽  
Vol 115 (11) ◽  
pp. 925-927 ◽  
Author(s):  
H. Pau ◽  
S. De ◽  
M. G. Spencer ◽  
P. R. M. Steele
Keyword(s):  
Malignant Melanoma ◽  
Metastatic Melanoma ◽  
Surgical Excision ◽  
Metastatic Malignant Melanoma ◽  
Cutaneous Malignant Melanoma ◽  
Diagnosis And Treatment ◽  
Metastatic Tumour ◽  
Previously Treated

Metastatic malignant melanoma of the larynx is considered to be extremely rare by most authors. This paper describes a 78-year-old patient, previously treated for cutaneous malignant melanoma and intestinal fibrosarcoma, who presented with stridor due to a metastatic melanoma in the larynx. It was a pedunculated lesion and surgical excision of the lesion was accomplished with a tonsillar snare. This paper further discusses the evolving history, diagnosis and treatment of this metastatic tumour, and reviews the literature regarding previously reported cases.

scholarly journals Effective Immunotherapy in Bone Marrow Metastatic Melanoma Presenting with Disseminated Intravascular Coagulopathy

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Bolanle Gbadamosi ◽  
Daniel Ezekwudo ◽  
Bhadresh Nayak ◽  
Zhou Yu ◽  
Sandra Gjorgova-Gjeorgjievski ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Malignant Melanoma ◽  
Metastatic Melanoma ◽  
Checkpoint Inhibitors ◽  
Treatment Options ◽  
Metastatic Malignant Melanoma ◽  
Critically Ill Patient ◽  
Low Grade ◽  
Disseminated Intravascular Coagulopathy ◽  
Intravascular Coagulopathy

Malignant melanoma is responsible for the majority of skin cancer deaths and is increasing in prevalence. Bone marrow (BM) involvement by melanoma is rare in the absence of widespread visceral disease. Here, we report the case of a 30-year-old female who presented to the hospital with back pain, low-grade fever, and easy bruising. She was found to be bicytopenic and in disseminated intravascular coagulopathy (DIC). Surprisingly, BM biopsy showed extensive involvement by metastatic malignant melanoma in the absence of visceral or brain metastasis. The unique presentation of this case and the challenge of management of a potentially treatable cancer in a critically ill patient are discussed, alongside a review of published cases of metastatic melanoma in the BM and an exploration of currently available treatment options. The excellent response of our patient to combined immune checkpoint inhibitors has yet to be paralleled in the available literature.

scholarly journals A Rare Case of Metastatic Malignant Melanoma to the Colon from an Unknown Primary

2014 ◽  
Vol 2014 ◽  
pp. 1-4
Author(s):  
Preethi Reddy ◽  
Courtney Walker ◽  
Bianca Afonso
Keyword(s):  
Overall Survival ◽  
Gastrointestinal Tract ◽  
Malignant Melanoma ◽  
Metastatic Melanoma ◽  
Rare Case ◽  
Metastatic Malignant Melanoma ◽  
Unknown Primary ◽  
Gastrointestinal Metastasis ◽  
Low Prevalence

Metastatic melanoma from an unknown primary (MUP) is rare; its occurrence in the gastrointestinal tract is of exceedingly low prevalence. We report a case of a 73-year-old man with metastatic malignant melanoma to the colon from an unknown primary. The rarity of MUP and importance of screening for gastrointestinal metastasis in patients with malignant melanoma are discussed along with the role of surgical resection in improving prognosis and overall survival.

scholarly journals Case of Metastatic Malignant Melanoma Simulating Granuloma Annulare

2021 ◽  
Vol 5 (3) ◽  
pp. 289-292
Author(s):  
Haley Danielle Heibel ◽  
Parneet Dhaliwal ◽  
Etan Marks ◽  
Clay J. Cockerell
Keyword(s):  
Malignant Melanoma ◽  
Metastatic Melanoma ◽  
Immunohistochemical Staining ◽  
Previous History ◽  
Metastatic Malignant Melanoma ◽  
Granuloma Annulare ◽  
Diagnostic Challenge ◽  
Clinical Presentations ◽  
History Of ◽  
High Index Of Suspicion

Malignant melanoma and particularly metastatic melanoma represent a diagnostic challenge due to the wide variety of histologic patterns, resemblance to benign entities, and extensive range of clinical presentations.  A high index of suspicion for melanoma is important for accurate diagnosis, especially when there is a previous history of malignancy.  Here, we present a patient with a history of melanoma and locally metastatic melanoma, who subsequently developed a nodule on his right forearm near the site of his previous melanoma excision.  Histologically, the melanoma appeared as granuloma annulare (GA) with benign cytologic features, but was identified as metastatic melanoma using SOX-10 immunohistochemical staining.  Other malignancies, including lymphomas, leukemias, sarcomas, and cutaneous metastases of internal malignancies, have mimicked GA and interstitial granulomatous processes.  Therefore, further immunohistochemical staining should be performed to assess for metastatic disease in the setting of a histological pattern that resembles a benign granulomatous process in a patient with a history of malignancy, including malignant melanoma.

Metastatic Malignant Melanoma in Prepubertal Children

PEDIATRICS ◽  
1975 ◽  
Vol 55 (2) ◽  
pp. 191-204
Author(s):  
Daniel J. Trozak ◽  
Willard D. Rowland ◽  
Funan Hu
Keyword(s):  
Malignant Melanoma ◽  
Metastatic Melanoma ◽  
Correct Diagnosis ◽  
Metastatic Malignant Melanoma ◽  
Epithelioid Cell ◽  
Low Grade ◽  
Microscopic Appearance ◽  
Malignant Melanomas ◽  
Real Nature ◽  
Benign Nevi

Medical literature is full of involved and Confusing reports on the genesis, incidence, and development of metastatic melanoma in children. The reason for this confusion can be found in the early uncertainties that surrounded the real nature and correct diagnosis of metastatic melanoma in the prepubertal child. Before 1950, reports of melanomas with metastases in children were rare, poorly documented, and in many cases erroneous.1-4 In particular, benign nevi (now known as benign juvenile melanoma) went unrecognized and because of their alarming microscopic features were often diagnosed as malignant melanomas. For example, deceived by the predilection of this nevus for childhood, its frightening appearance, and failure to metastasize, Pack and Anglem wrote: ". . . . although malignant melanomas are found in infancy and childhood, they are of low grade malignancy and seldom metastasize" In a later paper, Pack6 coined the term "prepubertal melanoma" for those nonmetastasizing pigmented tumors of children which were microscopically indistinguishable from melanoma. He suggested removal before puberty when endocrinologic stimulation rendered certain of them capable of metastasis. Other investigators also noted this seeming disparity between microscopic appearance and clinical behavior.7 In 1948, Spitz8 provided the criteria for separating this unusual-looking nevus from malignant melanoma and termed it "juvenile melanoma." Later she and Allen9 showed that although these lesions are not restricted to children, they are much more common before puberty.* Subsequent authors10-13 have also classified juvenile melanoma among the benign nevi and the term spindle or epithelioid cell nevus10,12,13 is now preferred. McWhorter and Woolner13 in 1954 reviewed the subject of malignant melanoma in children and suggested that the favorable prognosis was spurious and due to the erroneous classification of spindle and epithelioid cell nevi under the former agnosis.

Immunomodulatory effects of bevacizumab in metastatic malignant melanoma.

2012 ◽  
Vol 30 (30_suppl) ◽  
pp. 82-82
Author(s):  
Aaron Scott Mansfield ◽  
Wendy Kay Nevala ◽  
Svetomir Markovic
Keyword(s):  
Malignant Melanoma ◽  
Metastatic Melanoma ◽  
Metastatic Malignant Melanoma ◽  
Immunomodulatory Effect ◽  
Peripheral Blood Mononuclear ◽  
Cell Counts ◽  
Ongoing Work ◽  
Novel Therapeutic Strategies ◽  
Cell Phenotypes

82 Background: Metastatic malignant melanoma is a nearly uniformly fatal disease. Systemic therapy has notable but limited success. Novel therapeutic strategies are urgently needed. To that end, we’ve pursued combinatorial therapeutics using conventional chemotherapy added to an inhibitor of angiogenesis (bevacizumab) with some evidence of clinical benefit. Preliminary analysis of one of our trials suggested a previously unrecognized immunomodulatory effect of bevacizumab when added to chemotherapy in patients with metastatic melanoma, and this may have a potential impact on clinical outcome. Herein we evaluate the immunomodulatory effect of bevacizumab when added to chemotherapy in patients with metastatic melanoma. Methods: We measured levels of peripheral blood mononuclear cell phenotypes in addition to 42 cytokines, chemokines and growth factors in plasma of 55 patients who received albumin-bound paclitaxel and carboplatin (AC) and of 73 patients who received AC with bevacizumab (ACB) on clinical trials N057e and N0775 respectively. The relative percent change in PBMC cell counts and cytokine levels were determined from baseline at their restaging evaluation after two cycles of therapy. The Mann Whitney U test was used to compare responses between the groups. Results: There was a significant increase in CD197+type 1 macrophages in the group that received ACB (35.3%, -11.8-142.7%) compared to AC (-11.6%, -45.9-38.3%; p=0.004). There was a significant decrease in IL-6 in the group that received ACB (-42.4%, -87.7-0.0%) compared to AC (28.4%, -37.4-480%; p=0.0018). Conclusions: The addition of bevacizumab to chemotherapy for the treatment of metastatic melanoma modulates cellular immunity and a pro-inflammatory cytokine. Patients who received bevacizumab had a significant increase in CD197+ type 1 macrophages and a significant decrease in IL-6. Clinical significance of these findings is the subject of ongoing work.

Combination Chemotherapy with 1-Methyl-1-Nitrosourea and Cyclophosphamide in Metastatic Melanoma

1978 ◽  
Vol 64 (1) ◽  
pp. 89-94 ◽  
Author(s):  
Krsto Kolarić ◽  
Anton Roth ◽  
Vera Fuss
Keyword(s):  
Body Weight ◽  
Malignant Melanoma ◽  
Antitumor Activity ◽  
Lymph Nodes ◽  
Metastatic Melanoma ◽  
Combination Chemotherapy ◽  
Tumor Regression ◽  
Objective Response ◽  
Metastatic Malignant Melanoma ◽  
Melanoma Metastasis

Twenty one patients with advanced metastatic melanoma were treated with a combination of 1-methyl-1-nitrosourea (MNU) and cyclophosphamide. AH the patients had not previously been treated with cytostatics. MNU in the dose of 4 mg/kg and cyclophosphamide in the dose of 8 mg/kg body weight was administered daily. The drugs were given in 6 day cycles. Objective response (> 50% tumor regression) was obtained in 8 (38%) of the 21 treated patients, with 2 complete and 6 partial remissions. The duration of remission was 2–12 months (M = 6.2 months). Injections of MNU caused nausea and vomiting in approximately all the treated patients. Combination of these drugs, however, produced myelodepression in 33% of treated patients. This combination of drugs showed antitumor activity in metastatic malignant melanoma, particularly in melanoma metastasis of the lung, brain and lymph nodes and needs further investigation.

Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group study.

1984 ◽  
Vol 2 (4) ◽  
pp. 316-319 ◽  
Author(s):  
J M Quagliana ◽  
R L Stephens ◽  
L H Baker ◽  
J J Costanzi
Keyword(s):  
Malignant Melanoma ◽  
Complete Remission ◽  
Metastatic Melanoma ◽  
Phase Ii Study ◽  
Metastatic Malignant Melanoma ◽  
Gastrointestinal Toxicity ◽  
Oncology Group ◽  
Oncology Group Study ◽  
Southwest Oncology Group ◽  
Southwest Oncology Group Study

A phase II study using vindesine (3 mg/m2 by slow intravenous push at seven to 14 day intervals) was carried out in 42 patients with metastatic melanoma. There was one complete remission (2.5%) of greater than 12 months duration; seven partial remissions (17.5%) of two, three, three, four, five, six and eight months duration; 11 with no change (27.5%) of one to 10 months duration; and 21 (52.5%) patients with increasing disease. Toxicity included neutropenia, neurotoxicity, phlebitis and cellulitis at the site of injection, alopecia, fever and chills, myalgias, and gastrointestinal toxicity. It was concluded that vindesine does have activity in some patients with metastatic malignant melanoma. Further studies in previously untreated patients are warranted.

scholarly journals Diffuse melanosis secondary to metastatic melanoma in a Nelore bull

2021 ◽  
Vol 14 (3) ◽  
pp. 191-198
Author(s):  
Jacqueline de Jesus ◽  
◽  
Andrieli Bortolini ◽  
Gabriela de Almeida ◽  
Bárbara de Oliveira ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Urinary Bladder ◽  
Antibiotic Therapy ◽  
Lymph Nodes ◽  
Metastatic Melanoma ◽  
Clinical Signs ◽  
Metastatic Malignant Melanoma ◽  
Dark Urine ◽  
Spleen And Lymph Nodes ◽  
Black Discoloration

We report a case of diffuse melanosis secondary to metastatic malignant melanoma in a Nelore bull. Clinical signs included isolation from the herd, epistaxis, hyperthermia, pale ocular membranes, mucoid diarrhea and dark urine. Despite anti-inflammatory and antibiotic therapy, the bull died 45 days after the onset of the clinical signs. The most striking lesion was diffuse black discoloration to the visceral organs including liver, spleen, lungs, lymph nodes, and kidneys; all these affect organs were moderately enlarged”. The urine was black. Histologically, 50-80% of the parenchyma of the liver, spleen and lymph nodes was obliterated by aggregates of melanin-loaded neoplastic melanocytes. Those neoplastic cells also occurred within capillaries of the liver, spleen, lymph nodes, urinary bladder, lungs and kidneys. Immunohistochemistry of neoplastic melanocytes was positive for Melan A and PNL2 markers. Abundant brown to black pigment was found in melanophages in the lungs, confirmed by IBA1 immunohistochemistry.

Sign in / Sign up

Export Citation Format

Share Document